ReviewJournal of preventive medicine and hygiene2022
Dietary supplements for polycystic ovary syndrome.
Review in Journal of preventive medicine and hygiene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials.BMC endocrine disorders · 2026Pooled it
- Efficacy of dietary supplements as an adjunctive therapy for polycystic ovary syndrome: an umbrella meta-analysis.Frontiers in nutrition · 2025Pooled it
- The Effect of Vitex Agnus - Castus Plant on Some Markers of Oxidative Stress, Lipid Profile and Insulin Resistance in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind Controlled Clinical Trial Study.JBRA assisted reproduction · 2026Trial
- Astaxanthin treatment decreases pro-inflammatory cytokines and improves reproductive outcomes in patients with polycystic ovary syndrome undergoing assisted reproductive technology: A randomized clinical trial.Inflammopharmacology · 2024Trial
- Polycystic Ovary Syndrome (PCOS): A Comprehensive Review of Clinical Approaches, Functional Bioactives, and Nutritional Interventions.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms.Frontiers in reproductive health · 2026Review
- NSUN7-mediated m5C methylation of NLRP3 promotes pyroptosis in ovarian granulosa cells in polycystic ovary syndrome.Scientific reports · 2025Article
- The Role of Pharmacists in Identifying and Preventing Drug-Related Problems in PCOS Management.Pharmacy (Basel, Switzerland) · 2025Review
- Effect of nutritional intervention combined with vitamin D on glucose metabolism, sex hormones and inflammatory factors in patients with polycystic ovary syndrome.Journal of medical biochemistry · 2025Article
- Formononetin ameliorates polycystic ovary syndrome through suppressing NLRP3 inflammasome.Molecular medicine (Cambridge, Mass.) · 2025Article
- Beneficial Effects of Curcumin in Polycystic Ovary Syndrome: A Review of Recent Literature and Underlying Mechanisms.Current medicinal chemistry · 2025Review
- The Discourse Surrounding Polycystic Ovary Syndrome on TikTok: A Social Media Analysis.Healthcare (Basel, Switzerland) · 2024Review
- Mandibular Endochondral Growth Is Specifically Augmented by Nutritional Supplementation with Myo-Inositol Even in Rabbits.Dentistry journal · 2024Article
- Dietary supplements in polycystic ovary syndrome-current evidence.Frontiers in endocrinology · 2024Review
- Causal relationship between fertility nutrients supplementation and PCOS risk: a Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Therapeutic Effects and Molecular Mechanism of Chlorogenic Acid on Polycystic Ovarian Syndrome: Role of HIF-1alpha.Nutrients · 2023Review
- Neurobiology and Applications of Inositol in Psychiatry: A Narrative Review.Current issues in molecular biology · 2023Review
- Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most prevalent female endocrine reproductive disorders, affecting between 4 to 18% of the women in their reproductive age. It is generally characterized by several clinical aspects, among which anovulation, inflammation and infertility. Moreover, PCOS has several health implications, including increased metabolic, reproductive, and psychological risks. Previously, metformin and to some extent thiazolidinediones were considered as drug of choice for PCOS management, but they had several side-effects, and controversial results were obtained about their efficiency, especially in non-insulin-resistant non-obese patients. Thus, alternative treatment options are now being studied for PCOS, including different natural molecules and complementary medicines (CM) for the improvement of their health, wellbeing and fertility. Recently, treatment of PCOS patients with different natural molecules, coming from nutritional supplements and herbal medicines, has attained satisfactory results with the absence of any side effects. In this review, four natural molecules, curcumin, vitamin D, inositol and CoQ10 are discussed for their therapeutic ability. These molecules proved to decrease insulin sensitivity and inflammation, to improve the restoration of ovarian function, and they could restore hormonal balance and regulate the menstrual cycle, all of which are the main features and major concerns for women suffering from PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.